Nuvalent Appoints Dr. Arvind Sood as Chief Medical Officer
Ticker: NUVL · Form: 8-K · Filed: Jul 22, 2024 · CIK: 1861560
Sentiment: neutral
Topics: leadership-change, executive-appointment, oncology
TL;DR
Nuvalent just hired a new CMO, Dr. Arvind Sood, to lead their oncology drug development.
AI Summary
On July 22, 2024, Nuvalent, Inc. announced the appointment of Dr. Arvind Sood as Chief Medical Officer. Dr. Sood brings extensive experience in oncology drug development and will lead Nuvalent's clinical strategy. This appointment is effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer with a strong background in oncology drug development is a key leadership change that could impact the company's future clinical trial progress and strategic direction.
Risk Assessment
Risk Level: medium — Leadership changes, especially in critical roles like Chief Medical Officer, can introduce uncertainty regarding future strategy and execution.
Key Numbers
- 001-40671 — SEC File Number (Identifies Nuvalent's filings with the SEC.)
- 81-5112298 — IRS Employer Identification No. (Nuvalent's tax identification number.)
Key Players & Entities
- Nuvalent, Inc. (company) — Registrant
- Dr. Arvind Sood (person) — Newly appointed Chief Medical Officer
- July 22, 2024 (date) — Date of report and earliest event
- 001-40671 (company) — SEC File Number
- 000000000 (company) — IRS Number
FAQ
Who is the new Chief Medical Officer at Nuvalent, Inc.?
Dr. Arvind Sood has been appointed as the new Chief Medical Officer of Nuvalent, Inc.
When was this appointment announced?
The appointment was announced on July 22, 2024.
What is Dr. Sood's primary responsibility at Nuvalent?
Dr. Sood will lead Nuvalent's clinical strategy, leveraging his experience in oncology drug development.
What is Nuvalent, Inc.'s principal executive office address?
Nuvalent, Inc.'s principal executive offices are located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142.
What is Nuvalent's SEC file number?
Nuvalent's SEC file number is 001-40671.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-07-22 06:33:12
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq
Filing Documents
- nuvl-20240722.htm (8-K) — 36KB
- 0000950170-24-085044.txt ( ) — 155KB
- nuvl-20240722.xsd (EX-101.SCH) — 31KB
- nuvl-20240722_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On July 22, 2024, Nuvalent, Inc. announced the initiation of HEROEX-1, its Phase 1a/1b clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer, with the dosing of the first patient in the trial. The HEROEX-1 trial will evaluate the overall safety and tolerability of NVL-330. Additional objectives include determination of the recommended Phase 2 dose, characterization of the pharmacokinetic profile, and preliminary evaluation of anti-tumor activity. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvalent, Inc. Date: July 22, 2024 By: /s/ Deborah A. Miller Deborah A. Miller, Ph.D. Chief Legal Officer and Secretary